enGene Therapeutics (ENGN) Total Liabilities (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Total Liabilities of $52.4 million for Q2 2026, up 33.02% year-over-year from $39.4 million in Q2 2025, and down 5.78% quarter-over-quarter from $55.6 million in Q1 2026.
enGene Therapeutics (ENGN) Total Liabilities (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Total Liabilities for 5 consecutive years, with $52.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities rose 33.02% year-over-year to $52.4 million; the TTM figure through Apr 2026 stood at $52.4 million (up 33.02% YoY), while the FY2025 annual figure was $53.8 million, up 39.41% from the prior year.
- Total Liabilities fell to $52.4 million in Q2 2026 per ENGN's latest filing, from $55.6 million in the prior quarter.
- Across five years, Total Liabilities topped out at $55.6 million in Q1 2026 and bottomed at $14.5 million in Q4 2023.
- Historically, Total Liabilities has averaged $40.0 million across 5 years, with a median of $39.0 million in 2024.
- Annual changes were most pronounced in 2023 — Total Liabilities slumped 69.47% — and 2024, when it soared 166.43%.
- enGene Therapeutics' Total Liabilities stood at $47.4 million in 2022, then plunged by 69.47% to $14.5 million in 2023, then surged by 166.43% to $38.6 million in 2024, then soared by 39.41% to $53.8 million in 2025, then fell by 2.61% to $52.4 million in 2026.
- Business Quant data shows ENGN's Total Liabilities at $52.4 million in Q2 2026, $55.6 million in Q1 2026, and $53.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 52.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 52.36 Mn |
| Jan 31, 2026 | 55.57 Mn |
| Oct 31, 2025 | 53.76 Mn |
| Jul 31, 2025 | 44.88 Mn |
| Apr 30, 2025 | 39.36 Mn |
| Jan 31, 2025 | 35.98 Mn |
| Oct 31, 2024 | 38.56 Mn |
| Jul 31, 2024 | 36.55 Mn |
| Apr 30, 2024 | 30.56 Mn |
| Jan 31, 2024 | 31.04 Mn |
| Oct 31, 2023 | 14.47 Mn |
| Oct 31, 2022 | 47.41 Mn |